Farms.com Home   Ag Industry News

EPA FInds No Benefit of Neonic Seed Treatments In Soybeans.

U.S. EPA Finds Negligible Benefits of Neonicotinoid Seed Treatment In Soybeans.

By Joe Dales, Farms.com

The agriculture use of the neonicotinoid class seed treatments is being reviewed by regulators in the United States and Canada after concerns have been raised that the products may contribute to the decline in populations of honeybees.

The EPA in a news statement released Thursday reports that an analysis of neonicotinoid seed treatments has concluded that there is "little or no increase in soybean yields using most neonicotinoid seed treatments when compared to using no pest control at all."

"We have made the review of neonicotinoid pesticides a high priority," Jim Jones, assistant administrator for EPA's Office of Chemical Safety and Pollution Prevention, said in a statement. "In our analysis of the economic benefits of this use we concluded that, on a national scale, U.S. soybean farmers see little or no benefit from neonicotinoid seed treatments."

Honey producers say neonics weaken the bees and worsen the effects of parasitic mites and viruses, and contribute to increasing overwintering deaths.

The EPA will continue to analyze the neonicotinoid seed treatments in an assessment of the risks and benefits under registration review, with a special focus on the negative impact on pollinators.

EPA does recognize that neonicotinoid seed treatments, however, could provide an insurance benefit against sporadic and unpredictable insect pests, but this potential benefit is not likely to be large or widespread throughout the United States.

For more information and to find the EPA report, click on the following link.

http://www2.epa.gov/pollinator-protection/benefits-neonicotinoid-seed-treatments-soybean-production


Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.